Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.

Abstract

Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.

• Authors: Jiamin Cao, Feng Zhang, Wei Xiong
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 18 Pg. 4421-4430 ( 2023) ISSN: 1178-2013 [Electronic] New Zealand
• PMID: 37551274 (Publication Type: Journal Article, Review)
• Copyright: © 2023 Cao et al.

Chemical References

• Vascular Endothelial Growth Factor A
• Aptamers, Nucleotide

Topics

• Humans
• Vascular Endothelial Growth Factor A
• Ophthalmology
• Macular Degeneration
• Aptamers, Nucleotide (therapeutic use, pharmacology)
• Diabetic Retinopathy (drug therapy)
• Glaucoma (drug therapy)
• Acceleration